Preferences help
enabled [disable] Abstract
Number of results
2014 | 9 | 1 | 108-114
Article title

The predictors of cholelithiasis in female patients with metabolic syndrome

Title variants
Languages of publication
Cholesterol gallstone disease is often associated with the metabolic syndrome. Female gender is an unmodifiable risk factor for cholelithiasis and, in its turn, the metabolic syndrome features a sexual dimorphism which warns that a global approach might overlook important discrimination. We carried out a retrospective analytical case-control study in order to perform a comparative analysis between two groups of female patients with metabolic syndrome and gallstones (n=60) or without gallstones (n=65). All the patients were investigated by abdominal ultrasound and met at least three criteria for the diagnosis of metabolic syndrome. Cases and controls were compared regarding anthropometric measurements, a complex lipid profile, and liver function tests. The risks associated with the likelihood of gallstones were estimated by means of cross-tabulation. In order to rank the significant variables we developed a binary logistic regression model which identified lean body weight ≤ 46.44 kg (OR 0.165; 95% CI 0.045–0.611; P = 0.007), total cholesterol ≥ 4.9 mmol/L (OR 15.948; 95% CI 2.700–94.205; P = 0.002), and direct bilirubin > 5.1 µmol/L (OR 0.056; 95% CI 0.013–0.235; P < 0.001), as variables with significant probability of association with the risk of gallstones in women with metabolic syndrome.
Physical description
1 - 2 - 2014
4 - 2 - 2014
  • [1] Shaffer E.A., Gallstone disease: Epidemiology of gallbladder stone disease, Best Pract. Res. Clin. Gastroenterol., 2006, 20(6), 981–996[Crossref]
  • [2] Méndez-Sánchez N., Chavez-Tapia N.C., Motola-Kuba D., Sanchez-Lara K., Ponciano-Rodríguez G., Baptista H., Ramos M.H., Uribe M., Metabolic syndrome as a risk factor for gallstone disease, World J. Gastoenterol., 2005, 11(11), 1653–1657
  • [3] Grundy S.M., Cholesterol gallstones: a fellow traveler with metabolic syndrome? Am. J. Clin. Nutr., 2004, 80(1), 1–2
  • [4] Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C. Jr., Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association, Circulation, 2009, 120, 1640–1645 [Crossref]
  • [5] Kuk J., Ardern C.I., Age and sex differences in the clustering of metabolic syndrome factors, Diabetes Care, 2010, 33, 2457–2461[Crossref]
  • [6] Stinton L.M., Myers R.P., Shaffer E.A., Epidemiology of gallstones, Gastroenterol. Clin. N. Am., 2010, 39(2), 157–169[Crossref]
  • [7] Lobo R.A., Metabolic syndrome after menopause and the role of hormones, Maturitas, 2008, 60, 10–18[WoS][Crossref]
  • [8] Boland L.L., Folsom A.R., Rosamond W.D., Atherosclerosis Risk in Communities (ARIC) Study Investigators. Hyperinsulinemia dyslipidemia and obesity as risk factors for hospitalized gallbladder disease. A prospective study, Ann. Epidemiol., 2002, 12, 131–140[Crossref]
  • [9] Mosteller, R.D., Simplified calculation of body surface area, N. Engl. J. Med., 1987, 317(17), 1098 (letter)
  • [10] Morgan D.J., Bray K.M., Lean body mass as a predictor of drug dosage. Implications for drug therapy, Clin. Pharmacokinet., 1994, 26(4), 292–307[Crossref]
  • [11] Green B., Duffull S.B., What is the best size descriptor to use for pharmacokinetic studies in the obese? Br. J. Clin. Pharmacol., 2004, 58(2), 119–133[Crossref]
  • [12] Nam B.H., Kannel W.B., D’Agostino R.B., Search for an optimal atherogenic lipid risk profile: from the Framingham Study, Am. J. Cardiol., 2006, 97, 372–375[Crossref]
  • [13] Millán J., Pintó X., Muñoz A., Zúñiga M., Rubiés-Prat J., Pallardo L.F., Masana L., Mangas A., Hernandez-Mijares A., Gonzalez-Santos P., Ascaso J.F., Pedro-Botet J., Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention, Vasc. Health Risk Manag., 2009, 5, 757–765
  • [14] Kahn H.S., The Lipid Accumulation Product Is Better Than BMI for Identifying Diabetes. A population-based comparison, Diabetes Care, 2006, 29(1), 151–153[Crossref]
  • [15] McLaughlin T., Reaven G., Abbasi F., Lamendola C., Saad M., Waters D., Simon J., Krauss R.M., Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am. J. Cardiol., 2005, 96(3), 399–404[Crossref]
  • [16] Ruhl C.E., Everhart J.E., Association of diabetes, serum insulin, and C-peptide with gallbladder disease, Hepatology, 2000, 31(2), 299–303[Crossref]
  • [17] Tsai C.J., Leitzmann M.F., Willett W.C., Giovannucci E.L., Prospective study of abdominal adiposity and gallstone disease in US men, Am. J. Clin. Nutr., 2004, 80(1), 38–44
  • [18] Chen L.Y., Qiao Q.H., Zhang S.C., Chen Y.H., Chao G.Q., Fang L.Z., Metabolic syndrome and gallstone disease, World J. Gastroenterol., 2012, 18(31), 4215–4220[Crossref]
  • [19] Sporea I., Goldis M., Mateoc A., Echographic screening concerning the incidence of gallstones in a general population, Gastroenterol., 1993, 104, A379
  • [20] Acalovschi M., Pascu M., Iobagiu S., Petrescu M., Olinici C.D., Increasing gallstones prevalence and cholecystectomy rate in a large Romanian town, Dig. Dis. Sci., 1995, 40, 2582–2586[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.